The innate immune system of mammals provides a rapid response to repel assaults from numerous infectious agents including bacteria, viruses, fungi, and parasites. A major component of this system is a diverse combination of cationic antimicrobial peptides that include the ␣-and ␤-defensins and cathelicidins. In this study, we show that 1,25-dihydroxyvitamin 
A major concern for public health in both developed and developing countries is the alarming increase of antibiotic resistance in bacteria (1) . Drug-resistant bacteria such as Pseudomonas aeruginosa and Staphylococcus aureus pose serious problems for immunocompromised persons and are major sources of life-threatening nosocomial infections. In 2000, nearly 660,000 cases of sepsis developed in the United States. This resulted in an in-hospital mortality rate of nearly 18% (2) . Among survivors of sepsis, an increased risk of death and decreased quality of life occurred after discharge from the hospital (3, 4) .
This impending crisis has spurred the search for new therapeutic agents to combat antibiotic resistance. One potential solution lies within a system all animals are "born with," the innate immune system responsible for keeping us healthy (5) . It provides animals the capacity to repel assaults quickly from numerous infectious agents including bacteria, viruses, fungi, and parasites (6 -11) . Diverse combinations of cationic antimicrobial peptides (AMPs) including ␣-and ␤-defensins and cathelicidins comprise a major component of this defense in mammals. Because bacteria have difficulty developing resistance against AMPs and are quickly killed by them, this class of antimicrobial agents is being commercially developed as a source of peptide antibiotics (1, 12, 13) . The majority of the pharmaceutical effort has concentrated on the development of topically applied agents (13) . The expense and difficulty of preparing large amounts of peptide and the uncertainty in systemic use of these peptides have slowed their development beyond topical treatments.
One AMP that shows promise is the human cathelicidin antimicrobial peptide (CAMP), also known as hCAP18/LL-37/FALL-39. It is the only known human cathelicidin. The cathelicidins are a family of proteins consisting of a C-terminal cationic AMP domain that is activated by cleavage from the N-terminal cathelin portion of the propeptide. The majority of the CAMP propeptide is stored in secondary or specific granules of neutrophils from which it can be released at sites of microbial infection (14) . In addition to neutrophils, various white blood cell populations express hCAP18. These include natural killer cells, ␥␦T cells, B cells, monocytes (15) , and mast cells (16) . CAMP/hCAP18 is secreted into the blood and significant levels are found in the plasma (17) .
CAMP is synthesized and secreted in significant amounts by those tissues that are exposed to environmental microbes. This includes the squamous epithelia of the mouth, tongue, esophagus, lungs, intestine, cervix, and vagina (18, 19) . In addition, it is produced by salivary and sweat glands (20, 20) , epididymis, testis (21) , and mammary glands (22) (23) (24) . Expression in these tissues results in secretion of the polypeptide in wounds (25) , sweat (26) , airway surface fluids (19) , seminal plasma (27) , and milk (22, 23) . CAMP/ hCAP18 possesses several important activities including bactericidal, anti-sepsis, chemoattraction, and promotion of angiogenesis and wound healing. The possibility of extrinsically manipulating endogenous expression of CAMP for systemic and localized therapeutic benefit is very attractive.
Since their discovery more than a decade ago, the majority of expression studies have been focused on the detection of cathelicidins in various tissues; however, the transcriptional mechanisms that regulate cathelicidin gene expression have not been adequately elucidated. Understanding the signaling pathways and the downstream transcription factors that regulate CAMP gene expression in a tissue-specific manner is crucial for designing approaches for therapeutic manipulation of endogenous gene expression. Because AMPs serve a role in host defense and may act as mediators of other biological processes, their expression is tightly regulated.
The experimental focus of this study was to identify extracellular signals and the downstream transcription factors that activate transcription of the CAMP gene, with the ultimate goal of extrinsically manipulating its endogenous expression for systemic and localized therapeutic benefit. We provide evidence that the CAMP gene is a direct target of the transcription factor vitamin D receptor (VDR) that mediates the strong up-regulation of CAMP in response to treatment of cells with 1,25-dihydroxyvitamin D 3 [1,25(OH) 2 D 3 or vitamin D 3 ] and its analogs. Induction of the endogenous CAMP by these relatively safe (FDA approved) compounds may provide important novel therapeutic uses from promotion of wound healing to protection against bacteremia and sepsis after surgery, chemotherapy, or severe burns.
MATERIALS AND METHODS

Tissue culture and reporter assays
The human myeloid leukemia cell lines U937, NB4, HL60, and ML1 were cultured in RPMI1640 (Invitrogen, Carlsbad, CA, USA) containing 10% fetal calf serum (FCS; Omega Scientific, Inc., Tarzana, CA, USA). Human bone marrow cells isolated from either two normal or one acute myeloid leukemia patient were cultured in RPMI1640 containing 10% FCS for short-term experiments. Bone marrow (BM) -derived macrophages (M) were obtained by culturing normal human bone marrow (NHBM) cells in RPMI1640 containing 10% FCS, 200 ng/mL GM-CSF, and 5% WeHi-3B conditioned medium (source of IL-3) for 14 days. The bone marrow samples were obtained from patients after informed consent was given. Approval for the collection of these samples was obtained from the Cedars-Sinai Medical Center Institutional Review Board. The immortalized keratinocyte cell line HaCat (a kind gift from Dr. Norbert Fusenig, Heidelberg, Germany) and colon cancer cell line HT29 were cultured in DMEM containing 10% FCS. All media were supplemented with antibiotics (100 units penicillin/streptomycin; Invitrogen). Cells were treated with various concentrations and durations of 1,25(OH) 2 Murine 32Dcl3 cells (a generous gift from Alan Friedman, Johns-Hopkins, Baltimore, MD, USA) were cultured in IMDM (Invitrogen) supplemented with 10% FCS and 10% Wehi3B-conditioned medium. Cells were treated with 1,25-dihydroxyvitamin D 3 or ethanol for 0, 24, and 48 h and total RNA was harvested. The 1,25(OH) 2 D 3 and compound I (both 0.05 g/mouse) were administered to beige/nude/x-linked (bnx) nu/nu nude mice every 2 days for 6 wk. The bone marrow cells were flushed from the femurs and total RNA was isolated. Bone marrow cells were flushed from femurs of VDR-deficient mice or wild-type littermates (28) . Red blood cells were lysed and cells were plated in IMDM supplemented with 10% FCS. Cells were treated with 1,25(OH) 2 D 3 or ethanol for 24 h and total RNA was harvested. BM-derived macrophages were obtained from VDR-deficient and wildtype murine femurs as described previously (29) . Cells were treated with ethanol or 1,25(OH) 2 D 3 for 0, 24, and 48 h and total RNA was harvested.
U937 cells were electroporated using a BTX T820 (Genetronics Biomedical, Ltd., San Diego, CA, USA). The settings were low voltage, 200 V, 10 ms, 1 pulse in 250 L of cells at 2 ϫ 10 7 cells/mL in a 4 mm cuvette. A total of 20 g plasmid was used per transfection. After transfection, cells were treated with 1,25(OH) 2 D 3 or vehicle at the concentration and times indicated in the figure legends. Cell lysates were prepared and luciferase activities determined using the dual luciferase assay system as described by the manufacturer (Promega, Madison, WI, USA). Transfection efficiency was normalized to the renilla luciferase expression vector phTKRL (Promega).
Recombinant plasmids
Primers 5Ј-CCGACGCGTCATACTGAGTCTCACTCTGTT-ACC-3Ј and 5Ј-CCGCTCGAGGGTCCCCATGTCTGCCTC-3Ј were used to amplify the human CAMP promoter (nucleotides -693 to ϩ14) from human genomic DNA (30) . This fragment was subcloned into the firefly luciferase reporter plasmid pXP2 (31) and called pXP2-CAMP-Luc. Subsequently deletion mutants pXP2-CAMP(⌬SmaI)-Luc and pXP2-CAMP(⌬HindIII)-Luc were generated by restriction enzyme digestion, fill-in, and religation of the purified linear plasmid. Constructs were verified by nucleotide sequencing.
Analysis of RNA and protein expression
Total RNA was prepared using Trizol Reagent (Invitrogen), electrophoresed through a formaldehyde-containing 1% agarose gel, and transferred to a positively charged nylon membrane (Hybond Nϩ) for Northern analysis (Amersham Pharmacia Biotech, Piscataway, NJ, USA). The blots were sequentially probed with 32 P-labeled DNA probes (Strip-EZ TM , Ambion, Inc., Austin, TX, USA) specific for the CAMP, CDllb, and ␤-actin mRNAs.
For quantitative real-time PCR (QRT-PCR), total RNA was prepared, treated with DnaseI (Invitrogen), and cDNAs were synthesized by reverse transcription using Superscript II reverse transcriptase as described by the manufacturer (Invitrogen). The cDNAs were then analyzed by QRT-PCR using a fluorescent probe (Applied Biosystems, Foster City, CA, USA) against CAMP (5Ј-6fam-ACCCCAGGCCCACGATGGAT-tamra-3Ј) or 18S (32) at a final concentration of 200 nM per reaction. Primers against CAMP (forward, 5Ј-GCTAACCTCTACCGC-CTCCT-3Ј and reverse, 5Ј-GGTCACTGTCCCCATACACC-3Ј) or 18S (32) were used at 600 nM per reaction. PCR was performed using HotMaster TM Taq polymerase (Eppendorf AG, Hamburg, Germany) on an iCycler PCR machine equipped with an optical module (Bio-Rad Laboratories, Hercules, CA, USA). The protocol was 95°C, 1 min followed by 45 cycles of 95°C, 15 s and 60°C, 1 min, during which time data were collected. Standard curves were generated by PCR using serial dilutions of known quantities of CAMP or 18S cDNA and were included on each plate to quantify the ng of CAMP or ng of 18S cDNA in each sample. PCR was performed in triplicate for each sample.
Primers against murine CAMP/CRAMP (forward, 5Ј-GCAGTTCCAGAGGGACGTC-3Ј and reverse, 5Ј-GTTCCTT-GAAGGCACATTGC-3Ј) were used at 200 nM per reaction. PCR was performed using SYBR green (Molecular Probes, Eugene, OR, USA) as described previously (32) . The protocol was 95°C, 1 min followed by 45 cycles of 95°C, 15 s; 60°C, 30 s; and 65°C, 1 min, during which time data were collected. The relative fold change between samples was determined using data normalized for 18S expression. Samples were analyzed in triplicate.
Western blot and immunfluorescent microscopy analyses were performed essentially as described previously (33) . The total cell lysates were electrophoresed through 20% polyacrylamide-SDS gels. The hCAP18 antibody was used at 2.0 g/mL for Western blot analysis and 4.0 g/mL for immunofluorescent (IF) microscopy (14) . The anti-GAPDH monoclonal antibody was used at a 1:10,000 dilution (Research Diagnostics, Inc., Flanders, NJ, USA).
Chromatin immunoprecipitation (ChIP) assays
The ChIP assays were performed essentially as described by the manufacturer (Upstate, Inc., Chalottesville, VA, USA). Briefly, ϳ1 ϫ 10 7 cells were incubated with vehicle or 1,25-dihydroxyvitamin D 3 (1ϫ10 Ϫ7 M for 4 h). Protein/DNA complexes were cross-linked in 1% formaldehyde for 10 min. The reaction was terminated with the addition of glycine to 0.125 M final concentration. The cells were washed in ice-cold PBS containing PMSF (10 g/mL), resuspended in 1 mL of SDS-lysis buffer containing protease inhibitors, and incubated on ice for 10 min. The lysates were sonicated 3ϫ, 10 s at 30% output to shear the DNA. The sonicated lysate was pelleted at 13K rpm for 10 min at 4°C. Supernatant (0.2 mL) was mixed with 1.8 mL of dilution buffer and precleared with protein A-agarose for 1 h on ice. Antibody (2 g) against VDR (mixed SC-1008 [1 g] and SC-1009 [1 g], Santa Cruz Biotechnology, Santa Cruz, CA, USA), C/EBPε (2 L) (34), preimmune serum, or no antibody was added and the samples incubated overnight at 4°C. A slurry of ssDNA/protein A agarose was added and the mixture was incubated with rocking overnight at 4°C. The agarose/antibody/protein/DNA complex was pelleted and washed in low salt (1ϫ), high salt (1ϫ), LiCl (1ϫ), and TE (2ϫ). The complex was removed from the protein A-agarose in elution buffer (2ϫ500 L); cross-links were reversed in 100 mM NaCl at 65°C for 4 h, proteinase K treated, phenol/chloroform extracted, and ethanol precipitated. The promoter fragment was detected by PCR using primers against the CAMP promoter (forward, 5Ј-ACCGTGC-CCTGCCTCATTC-3Ј and reverse, 5Ј-TGGTCCCCATGTCT-GCCTC-3Ј). The 430 bp fragment was cloned and sequenced to verify that the CAMP promoter was amplified. QRT-PCR was performed using SYBR Green (Molecular Probes, Eugene, OR, USA) essentially as described (32) .
RESULTS
Induction of CAMP gene expression by 1,25(OH) 2 D 3
In an initial screen to identify extracellular signals that might induce CAMP gene expression, we treated the myeloid leukemia cell line U937 with various inflammatory factors (LPS, TPA, TNF-␣, INF-␣, and INF-␥), cytokines and growth factors (IL-2, IL-6, GM-CSF and G-CSF) and seco-steroid hormones (DHT, estradiol, ATRA and 1,25(OH) 2 D 3 ) (Fig. 1A and data not shown).
As determined by QRT-PCR and Northern blot analyses, only 1,25(OH) 2 D 3 induced CAMP expression significantly (Fig. 1A, B) . The induction was also observed in HL60 (Fig. 1B, C) and NB4 (Fig. 1C) . Induction of the CAMP gene occurred by day 1 in the U937 and HL60 cell lines, but was stronger in the U937 cell line (Fig. 1B) . A time course of from 1 to 24 h in U937 indicated that CAMP induction began between 1 and 3 h after addition of 1,25(OH) 2 D 3 and prior to induction of the differentiation marker CDllb at 12 h (Fig.  1B) . CAMP induction continued throughout the 5 days of treatment and was dose responsive (Fig. 1B, C) . Each of the chemically synthesized 1,25(OH) 2 D 3 analogs-KH1060, EB1089, and compound I-strongly induced CAMP gene expression (Fig. 1D ). Levels of induction were similar to those observed for 1,25(OH) 2 D 3 . No induction was observed with ATRA (5ϫ10 Ϫ7 M, 1-5 days) in U937, HL60, and NB4 (Fig. 1A and data not shown). This is consistent with the inability of human myeloid leukemia cell lines to express significant levels of mRNAs for secondary granule genes even when induced to undergo granulocytic differentiation by ATRA (35) .
The induction of CAMP was blocked by actinomycin D, indicating it occurred at the level of transcription (Fig. 1E) . The data suggested that the human CAMP gene was a direct transcriptional target of the VDR. The steroid hormone receptor family members are generally present in the cytosol or bound to the DNA in an inactive state and require activation by binding ligand (36) . Upon binding to ligand, they immediately translocate to the nucleus and bind vitamin D response elements (VDREs) in target genes and induce gene expression. The model predicts that ongoing protein synthesis is not required for this process to occur. To test this, we treated U937 cells with 1,25(OH) 2 D 3 in the presence or absence of cyclohexamide (CHX) to block protein synthesis. Induction of CAMP gene expression occurred in the absence of ongoing protein synthesis (presence of CHX) (Fig. 1F ) . CHX did not induce CAMP gene expression (data not shown). These data further support the hypothesis that the CAMP gene is a direct target of the VDR and not activated by secondary events such as the synthesis of other transcription factors that are induced by VDR.
To determine the specificity of CAMP induction by 1,25(OH) 2 D 3 , we tested other neutrophil primary [MPO (myeloperoxidase) and HNP3 (␣-defensin)] and secondary [MMP8 (matrix metalloproteinase 8) and LTF (lactoferrin)] granule genes for induction. We did not observe induction of these genes after 24 h of treatment, whereas CAMP was significantly up-regulated (Fig. 1G ). The data demonstrate that the 1,25(OH) 2 D 3 induction of neutrophil granule genes is restricted primarily to CAMP.
Induction of CAMP is independent of monocytic differentiation
Vitamin D 3 promotes macrophage-like differentiation of U937 and HL-60 (37) . To determine whether differentiation was responsible for the induction of the CAMP gene in AML cell lines, we treated HL-60 and U937 cells with 1,25(OH) 2 D 3 or TPA. Both compounds promoted macrophage-like differentiation of these cells as demonstrated by the induction of the differentiation marker CDllb, but induction of CAMP mRNA was observed only with 1,25(OH) 2 D 3 , not TPA ( Fig.  2A) . The data suggested that induction of differentiation was not sufficient for CAMP expression. Furthermore, 1,25(OH) 2 D 3 induced expression of CAMP was observed in the AML cell line NB4, which does not undergo macrophage differentiation when treated with 1,25(OH) 2 D 3 (Fig. 1C) . Finally, to demonstrate that CAMP induction occurs in the absence of differentiation, we treated sub-lines derived from HL-60, which are unable to differentiate in response to vitamin D 3 (HL60R) or ATRA (HL60⌬404) with 1,25(OH) 2 D 3 and found that CAMP was induced in the absence or presence of differentiation (Fig. 2B, HL60R vs. HL60⌬404, respectively).
Induction of the CAMP gene occurs in bone marrow cells from normal humans and a patient suffering from acute myeloid leukemia
To determine whether CAMP induction by vitamin D 3 occurs in hematopoietic cells other than leukemia cell lines, we treated total bone marrow (BM) cells and BM-derived macrophages (BM M) from two normal individuals and BM cells from one AML patient with 1,25(OH) 2 D 3 in vitro. Total RNA was harvested, cDNAs synthesized, and the quantity of CAMP mRNA expression was determined by QRT-PCR using a Taqman probe assay (Fig. 2C) . As demonstrated previously, a strong induction of CAMP was observed for U937 treated with 1,25(OH) 2 D 3 (Fig. 2C, upper panel) . Similarly strong induction of CAMP was observed in two normal human bone marrow cell samples and in BM M (Fig. 2C, upper panel) . The AML cells had a high baseline level of CAMP expression, which was induced further in a dose-responsive manner by 6-and 11-fold (Fig. 2C, lower panel) . These data demonstrate that 1,25(OH) 2 D 3 can markedly enhance the expression level of CAMP mRNA in normal and diseased human BM cells and that the induction is not a cell line phenomenon.
The induction of CAMP by 1,25(OH) 2 D 3 was not limited to myeloid cells. We observed induction of CAMP mRNA in the keratinocyte cell line HaCat and the colon cancer cell line HT-29 by QRT-PCR (Fig. 2D) . Induction was not as robust as that observed in the myeloid cells.
To determine whether the induction of CAMP mRNA expression resulted in an increase of CAMP (hCAP18) protein expression, Western blot and immunofluorescent microscopy analyses were performed on U937 cells treated with 1,25(OH) 2 D 3 (Fig. 3A, B) . At 18 h and 36 h post-treatment, increased levels of hCAP18 were observed compared with untreated cells (Fig. 3A, B ). An ELISA performed on the medium from U937 cells treated for 24 h with ethanol or 1,25(OH) 2 D 3 showed that CAMP was secreted into the medium (Fig. 3C ).
Identification of a functional VDRE in the human CAMP promoter
We hypothesized the existence of a VDRE in the CAMP promoter to explain the strong induction of CAMP mRNA expression by exposure to vitamin D 3 . A search of the upstream region revealed a classical DR3-type VDRE (38) at -615 bp from the transcriptional start site (Fig. 4A) (30) . PCR was used to amplify the human CAMP promoter from nucleotides -693 to ϩ14 (30). This fragment was subcloned into the firefly luciferase reporter plasmid pXP2 and called pXP2-CAMP-Luc (Fig. 4A) . Subsequently, deletion mutants pXP2-CAMP(⌬SmaI)-Luc and pXP2-CAMP(⌬HindIII)-Luc were generated by restriction enzyme digestion using the SmaI and HindIII sites, respectively (Fig. 4A) .
The CAMP promoter constructs were transfected into U937 cells that were subsequently treated with vehicle or 1,25(OH) 2 D 3 . After 18 h treatment, cell lysates were prepared and dual luciferase assays were performed. In the absence of 1,25(OH) 2 D 3 , luciferase activity for all reporter constructs, including the empty parental vector, was similarly low (Fig. 4B) . This is consistent with the very low levels of endogenous CAMP mRNA expression in untreated U937. Upon treatment, the full-length promoter construct pXP2-CAMP-Luc was consistently activated 2-to 2.5-fold (Fig. 4B) . The deletion mutants pXP2-CAMP(⌬SmaI)-Luc and pXP2-CAMP(⌬HindIII)-Luc were not activated. pXP2-CAMP(⌬SmaI)-Luc still possesses the VDRE; however, the SmaI site used for the generation of the construct is immediately adjacent to the VDRE (Fig.  4A ), suggesting that a single or several nucleotides located 5Ј to the VDRE is required for the response. These data demonstrate that this VDRE is required for activation of the CAMP promoter by vitamin D 3 .
VDR binds to the CAMP promoter in cells
To determine whether VDR complexes were actually binding to the CAMP promoter, we performed ChIP assays on chromatin prepared from U937 cells treated with vehicle or 1,25(OH) 2 D 3 for 4 h (Fig. 4C) . Because the VDRE is located in a repetitive DNA element or short interspersed nuclear element (SINE), it was difficult to design primers for PCR that specifically amplified that region of the CAMP promoter (Fig. 4A,  shaded boxes) . Therefore, we designed primers to the nonrepetitive region near the transcriptional start site that specifically amplifies the CAMP promoter (Fig.  4A) . The chromatin was sheared to an average size of ϳ1 kb and immunoprecipitated with antibodies (Ab) specific for the VDR and C/EBPε proteins. C/EBPε activates CAMP gene expression (39) and was included as a positive control. For negative controls chromatin was immunoprecipitated with protein A-Sepharose (No Ab) or preimmune serum (Pre). The samples were amplified by conventional PCR and visualized by ethidium bromide staining (Fig. 4C, upper panel) or QRT-PCR (Fig. 4C, lower panel) . Extremely low background levels were detected in the negative controls (Fig. 4C , No Ab or Pre). A significant level of the promoter was immunoprecipitated by anti-VDR Ab (22-fold above background) without 1,25(OH) 2 D 3 treatment, and this increased by Ͼ 2-fold (48-fold above background) with treatment (Fig. 4C, lower panel) . Binding of C/EBPε to the promoter was similar under both conditions (76-and 89-fold), demonstrating that vitamin D 3 treatment is not increasing the amount of C/EBPε binding to the promoter (Fig. 4C) . These results indicated that VDR is binding to the CAMP promoter in both a ligand-dependent and -independent manner, consistent with current models of steroidhormone gene regulation.
Induction of CAMP by vitamin D 3 is not evolutionarily conserved
To elucidate further the role of the VDR in regulating CAMP gene expression, we examined the expression of the murine CAMP/CRAMP gene in RNA from untreated bone marrow cells from a VDR-deficient mouse and its wild-type littermate (Fig. 5A, left panel) . Bone marrow RNAs from C/EBPε-deficient and wild-type mice were included as controls (Fig. 5A, left panel) . As expected, the C/EBPε-deficient bone marrow lacked expression of CRAMP (40) . In contrast, CRAMP was 2 D 3 or vitamin D 3 compound I over 6 wk did not significantly alter CRAMP expression in bone marrow compared with a vehicle-treated mouse (Fig. 5A, middle  panel) . We did not observe induction of CRAMP in murine cell lines 32Dcl3 (Fig. 5, right panel) , NIH3T3 and Wehi3B (data not shown). Finally, CRAMP induction was not observed in C/EBPε-deficient or wild-type bone marrow cells cultured in vitro with 1,25(OH) 2 D 3 (Fig. 5B ) or in BM M from VDR-deficient or wild-type mice (Fig. 5C) . Indeed, an ϳ 2-fold decrease was observed by 24 h post-treatment (Fig. 5B, C) and 5-fold by 48 h (Fig. 5C) .
We compared genomes from human, chimpanzee, rat, dog, and mouse to determine conservation of the promoter region for each CAMP gene (Fig. 5D) . Though significant homology was observed, a gap was identified at -409 bp upstream from the start site of transcription in the human promoter. This was a due to a SINE conserved only in the human and chimpanzee genomes and absent in the others (Fig. 5D) . The VDRE is located in this SINE. Thus, the mouse gene lacks a VDRE. This is consistent with the observed absence of CRAMP induction by vitamin D 3 .
DISCUSSION
In this study, we showed that 1,25-dihydroxyvitamin D 3 and three of its analogs induced expression of the antimicrobial peptide gene CAMP in AML, immortalized keratinocyte, and colon cancer cell lines, as well as bone marrow-derived macrophages and fresh bone marrow cells from normal individuals and one AML patient. The induction of antimicrobial protein genes by vitamin D 3 in myeloid cell lines was restricted primarily to CAMP.
Activation of the CAMP gene occurred via a consensus VDRE in the promoter that is bound by VDR. The VDR is expressed in a wide range of tissues; potentially, CAMP can be induced in all of these tissues. A recent report published during the preparation and submission of this manuscript reported findings consistent with those reported here (41). They observed induction by 1,25(OH) 2 D 3 in purified monocytes, neutrophils, and cell lines from lung as well as head and neck squamous cell carcinomas (41) . This study expands on these observations by demonstrating that not only does 1,25(OH) 2 D 3 induce CAMP gene expression, but so do analogs of vitamin D 3 . We showed that induction occurs in the cells of the bone marrow. Moreover, we discovered that the induction of CAMP by vitamin D 3 does not occur in mice. In fact, it appears that this mechanism is conserved in primates (humans and chimpanzees) and not in other mammals as suggested by the absence of the VDRE in the murine, rat, and canine CAMP promoters. The VDRE is present in a SINE element of the Alu-Sx subfamily. These elements can retrotranspose from a progenitor element to other locations in the genome during evolution. It would appear that this event occurred in a primate progenitor. Whether this element is conserved in all primates (other than humans and chimpanzees), as well as in New World and Old World monkeys, has not been determined.
The biological importance of this regulation is intriguing. Unfortunately, the murine model for VDRdeficiency will not prove useful. Perhaps examination of vitamin D-resistant rickets patient samples for CAMP expression may elucidate the importance of vitamin D 3 regulation of CAMP. It is interesting that these patients suffer from frequent dental abscesses (42) . Decreased expression of CAMP/hCAP18 protein may contribute to this as it does in Kostmann syndrome patients who lack hCAP18 (43) . Finally, CAMP/hCAP18 has immunomodulating properties ascribed to it. Whether or not it mediates some of those immunosuppressive properties of vitamin D 3 or acts to counter them needs clarification.
While these observations further expand the role of vitamin D 3 in immunomodulation in humans (44, 45) , they also indicate that the use of vitamin D 3 and its analogs provides a method to manipulate extrinsically the expression of CAMP. This may provide additional avenues for using relatively safe compounds in the treatment of human disease and injury. Enhancing the expression of CAMP expression could prove advantageous. Protective effects of CAMP overexpression in respiratory epithelia were observed in a cystic fibrosis model (46) . The systemic expression of CAMP/ hCAP18 in mice improved survival rates after intravenous injection of lipopolysaccharide (LPS) (47) . LPS is a component of the bacterial cell wall of gram-negative bacteria such as Escherichia coli or P. aeruginosa. Massive gram-negative bacterial infection can result in septic shock due to the large amounts of LPS present in the blood. Thus, hCAP18 may not only aid in clearance of bacterial infection, but may protect against the sepsis. This protection probably derives from the ability of CAMP to bind to LPS and neutralize it (48 -51) . The hCAP18 peptide has been shown to inhibit LPS-induced cellular responses such as release of TNF-␣, tissue factor, and nitric oxide, protecting mice and pigs from septic shock (48, 52) . In vitro, hCAP18 inhibits macrophage activation by LPS and other bacterial components (51) . If endogenous hCAP18 levels can be increased by extrinsic manipulation, then the potential exists to treat conditions that are susceptible to the development of sepsis. Boosting CAMP/hCAP18 levels potentially could protect against this condition after surgery and speed wound healing.
Like VDR expression, CAMP expression is widespread. It is important for barrier defenses in the skin. Mice deficient in CAMP are much more susceptible to skin infection than wild-type mice (53) . CAMP expression is up-regulated during cutaneous infection, injury, or inflammation (psoriasis) of the skin (54 -56) . Decreased levels of hCAP18 in the skin of individuals with atopic dermatitis (AD) correlates with their increased susceptibility to skin infection compared with those with psoriasis (55) . Vitamin D 3 and its analogs have proven safe and effective in the treatment of psoriasis. It remains to be determined whether CAMP induction occurs with the topical application of vitamin D 3 . If so, treatment of CAMP-deficient AD with vitamin D 3 may prove beneficial also.
Increasing CAMP expression by vitamin D 3 treatment may prove beneficial in other instances. CAMP is up-regulated in gastric inflammation caused by Heliobacter pylori infection (57) and infection of cultured epithelial cells with Salmonella and entero-invasive E. coli modestly induced CAMP mRNA expression (58) . In contrast, infection by Shigella spp. was reported to down-regulate CAMP mRNA expression in the colon (59) . Chronic oral bacterial infections occur in Kostmann syndrome patients who suffer from a severe chronic neutropenia. These patients lack expression of hCAP18 in their saliva, plasma, and neutrophils (43) . Patients suffering from specific granule deficiency lack expression of defensins and hCAP18 and suffer severe, recurrent bacterial infections (60) . Up-regulating CAMP/ hCAP18 expression in these conditions could prove therapeutically beneficial.
The induction of CAMP expression by cytokines and growth factors has been reported in a number of tissues; but 1,25(OH) 2 D 3 and its analogs are strikingly potent in myeloid cells. The induction was less striking in the HaCat and HT-29 cell lines, but combining vitamin D 3 treatment with other compounds known to activate CAMP expression may increase expression. Treatment of cultured keratinocytes or composite keratinocyte grafts with LPS or IL-1␣ induced CAMP expression (61); on the other hand, TNF-␣, Il-4, Il-6, IL-8, IL-10, and INF-␥ did not. The growth factor insulin-like growth factor-1 that is important in wound healing was found to induce both the CAMP mRNA and protein in primary human keratinocytes; TGF␣ and proinflammatory cytokines IL-1␤, IL-6, and TNF-␣ were not (62) . In epithelial cells of the colon, hCAP18 expression is restricted to differentiated cells in the human colon and ileum (58, 63) . Consistent with this, hCAP18 expression was induced by differentiation of colon epithelial cell lines and by short chain fatty acids independent of differentiation, but not by proinflammatory mediators including IL-1␣, IL-6, TNF-␣, INF-␥, LPS, or PMA (58, 63) . Combining those cytokines or growth factors with vitamin D 3 offers the possibility of obtaining synergistic activation of the CAMP gene. Such synergy was reported for LPS and vitamin D 3 in neutrophils (41) . Synergistic activation of the CAMP gene could prove useful in treating skin grafts for burn patients or in boosting immunity to opportunistic infections in chemotherapy patients.
